Erasca expects Phase 1 monotherapy expansion data for ERAS-0015 in H1 2027
Company anticipates preliminary Phase 1 monotherapy data for ERAS-4001 in H2 2026
Erasca expects current cash to fund planned milestones, including key data readouts and trial initiations
Overview
U.S. oncology drug developer's Q2 net loss widened yr/yr on higher R&D expenses
Company ended Q2 with $384 mln in cash, cash equivalents, and marketable securities
Raised $632 mln in July public offering to support pipeline advancement
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Erasca, Inc. is $21.50, about 18.7% above its August 10 closing price of $18.12
Result drivers and key details
Clinical trial spending - Higher R&D expenses driven by increased costs for clinical trials, preclinical studies, and discovery activities
ERAS•
